UBS Group AG GDTC — CYTOMED THERAPEUTICS LIMITED

Ownership history in UBS Group AG  ·  11 quarters on record

AI Ownership Summary

UBS Group AG reported CYTOMED THERAPEUTICS LIMITED (GDTC) in 11 quarterly 13F filings from 2024 Q3 through 2026 Q2. The latest visible filing shows GDTC at 0.00% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this GDTC ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was UBS Group AG's position in CYTOMED THERAPEUTICS LIMITED, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q2

GDTC was reported at 0.00% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.0% in 2025 Q2

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q3 to 2026 Q2

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

GDTC stock page UBS Group AG fund profile UBS Group AG full holdings
How UBS Group AG held GDTC — position size vs. price
% of Fund (quarterly)    GDTC price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 8 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q2 REDUCED 21.9% -9.7% ✅ 4,831 -1,351 -21.9% 0.00% $5K 2026-08-13 $0.85
2026 Q1 ADDED — — — 6,182 +5,117 +480.5% 0.00% $6K 2026-05-05 $0.92
2025 Q4 REDUCED 92.0% -25.4% ✅ 1,065 -12,224 -92.0% 0.00% $1K 2026-01-29 $0.84
2025 Q3 REDUCED 24.4% -27.6% ✅ 13,289 -4,292 -24.4% 0.00% $26K 2025-11-13 $1.92
2025 Q2 ADDED — — — 17,581 +3,134 +21.7% 0.00% $40K 2025-08-14 $1.78
2025 Q1 ADDED — — — 14,447 +4,349 +43.1% 0.00% $31K 2025-05-13 $2.27
2024 Q4 ADDED — — — 10,098 +10,037 +16454.1% 0.00% $34K 2025-02-14 $2.56
2024 Q3 REDUCED 98.3% +94.3% ❌ 61 -3,439 -98.3% 0.00% $96 2024-11-14 $2.12
3 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding GDTC

As of 2026 Q2 — sorted by position size

Axiom Investment Management LLC 3Y 0.0% OSAIC HOLDINGS, INC. 3Y 0.0%

FAQ About UBS Group AG and GDTC

These are the practical questions this page is built to answer before you even open the full history table.

How long has UBS Group AG reported owning GDTC?

UBS Group AG reported GDTC across 8 quarterly 13F filings, from 2024 Q3 through 2026 Q2.

What was the largest reported GDTC position in UBS Group AG's portfolio?

The largest reported portfolio weight for GDTC was 0.00% in 2025 Q2.

What is the latest reported GDTC position on this page?

The most recent filing on this page is 2026 Q2, when UBS Group AG reported 4,831 shares, equal to 0.00% of portfolio, with an estimated market value of $5K.

What does the chart on this GDTC ownership page compare?

The chart compares UBS Group AG's quarterly GDTC portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did UBS Group AG time their GDTC position?

Based on 13F filing dates vs. subsequent GDTC price moves, UBS Group AG correctly timed 3 out of 10 reported position changes (30%). The annualised alpha on GDTC relative to SPY over the holding period was +285.9%.

← Back to UBS Group AG Holdings